Adalimumab is a biologic medication used to treat various autoimmune diseases by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a protein involved in inflammation. It is commonly prescribed for conditions like rheumatoid arthritis, Crohn’s disease, psoriasis, ulcerative colitis, and ankylosing spondylitis. By blocking TNF-α, adalimumab helps reduce inflammation, pain, and tissue damage in these diseases. It is administered through subcutaneous injection and is available under the brand name Humira. While generally effective, adalimumab can have side effects, including increased risk of infections, and requires regular monitoring during treatment.
